JP2016528197A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528197A5 JP2016528197A5 JP2016524305A JP2016524305A JP2016528197A5 JP 2016528197 A5 JP2016528197 A5 JP 2016528197A5 JP 2016524305 A JP2016524305 A JP 2016524305A JP 2016524305 A JP2016524305 A JP 2016524305A JP 2016528197 A5 JP2016528197 A5 JP 2016528197A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- cycloalkyl
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 2
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- -1 C 1 -C 6 alkanoyl Chemical group 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010028143 Dioxygenases Proteins 0.000 claims 1
- 102000016680 Dioxygenases Human genes 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
- 0 C*C(**C(C1=CC=CI=C1)=C1*)=C1NC(N*)=O Chemical compound C*C(**C(C1=CC=CI=C1)=C1*)=C1NC(N*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361841448P | 2013-07-01 | 2013-07-01 | |
| US61/841,448 | 2013-07-01 | ||
| PCT/US2014/044992 WO2015002918A1 (en) | 2013-07-01 | 2014-07-01 | Ido inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528197A JP2016528197A (ja) | 2016-09-15 |
| JP2016528197A5 true JP2016528197A5 (enExample) | 2017-07-06 |
Family
ID=51257587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524305A Ceased JP2016528197A (ja) | 2013-07-01 | 2014-07-01 | Ｉｄｏ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9765018B2 (enExample) |
| EP (1) | EP3016932B1 (enExample) |
| JP (1) | JP2016528197A (enExample) |
| CN (1) | CN105473550B (enExample) |
| BR (1) | BR112015032595A8 (enExample) |
| CA (1) | CA2916615A1 (enExample) |
| EA (1) | EA029126B1 (enExample) |
| ES (1) | ES2719327T3 (enExample) |
| MX (1) | MX2015017486A (enExample) |
| WO (1) | WO2015002918A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012058065A1 (en) | 2010-10-26 | 2012-05-03 | Mars Incorporated | Boronates as arginase inhibitors |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| SI2970155T1 (en) * | 2013-03-15 | 2018-06-29 | Bristol-Myers Squibb Company | INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO) |
| MX2015017486A (es) | 2013-07-01 | 2016-03-21 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (dio). |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9895330B2 (en) * | 2013-07-11 | 2018-02-20 | Bristol-Myers Squibb Company | IDO inhibitors |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| HK1248235A1 (zh) * | 2015-05-15 | 2018-10-12 | 吉利德科学公司 | 具有作为吲哚胺2，3-二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物 |
| WO2017010106A1 (en) | 2015-07-14 | 2017-01-19 | Kyowa Hakko Kirin Co., Ltd. | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |
| EA201792256A1 (ru) | 2015-07-24 | 2018-07-31 | Ньюлинк Дженетикс Корпорейшн | Соли и пролекарства 1-метил-d-триптофана |
| BR112018005870A2 (pt) * | 2015-09-24 | 2018-10-16 | Glaxosmithkline Ip No 2 Ltd | composto, e, método de prevenção e/ou tratamento do hiv. |
| CA2998826A1 (en) * | 2015-09-24 | 2017-03-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Modulators of indoleamine 2,3-dioxygenase |
| WO2017133258A1 (zh) * | 2016-02-04 | 2017-08-10 | 西华大学 | 1h-吲唑类衍生物及其作为ido抑制剂的用途 |
| EP3416725A1 (en) | 2016-02-19 | 2018-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| US10696648B2 (en) * | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN109414421A (zh) * | 2016-05-04 | 2019-03-01 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| BR112018072669A2 (pt) | 2016-05-12 | 2019-02-19 | Glaxosmithkline Intellectual Property Development Limited | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratamento uma doença ou condição que se beneficiaria da inibição de ido1, e, uso de um composto ou sal |
| ES2939646T3 (es) | 2016-10-13 | 2023-04-25 | Juno Therapeutics Inc | Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano |
| AU2017382405B2 (en) | 2016-12-22 | 2021-12-16 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| WO2018136437A2 (en) | 2017-01-17 | 2018-07-26 | Tesaro, Inc. | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2018195649A1 (en) | 2017-04-26 | 2018-11-01 | Alberta Research Chemicals Inc. | Substituted tetrahydropyridine derivatives as ido-1 inhibitors and uses thereof |
| US11529819B2 (en) | 2017-06-08 | 2022-12-20 | Nippon Soda Co., Ltd. | Recording material and compound |
| AU2019205904A1 (en) | 2018-01-05 | 2020-06-18 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| CN110092750B (zh) | 2018-01-29 | 2023-07-21 | 北京诺诚健华医药科技有限公司 | 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用 |
| CN110526898A (zh) | 2018-05-25 | 2019-12-03 | 北京诺诚健华医药科技有限公司 | 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2020023355A1 (en) * | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN111153846B (zh) * | 2020-01-17 | 2021-08-31 | 中国药科大学 | 吡咯类化合物、其制备方法和药物组合物与用途 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| JP2024510949A (ja) | 2021-03-05 | 2024-03-12 | ウニヴェルシタット・バーゼル | Ｅｂｖ関連疾患又は状態の治療用組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2413418A1 (en) * | 2000-06-21 | 2001-12-27 | Joseph B. Santella | Piperidine amides as modulators of chemokine receptor activity |
| FR2878849B1 (fr) * | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
| US20080182882A1 (en) * | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0806794D0 (en) * | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| ES2638818T3 (es) * | 2010-12-22 | 2017-10-24 | Idogen Ab | Una composición que comprende al menos dos compuestos que inducen indolamina 2,3-dioxigenasa (IDO), para el tratamiento de un trastorno autoinmune o rechazo autoinmune de órganos |
| MX2015012056A (es) | 2013-03-15 | 2015-12-16 | Squibb Bristol Myers Co | Inhibidores de indolamina-2,3-dioxigenasa (ido). |
| MX2015017486A (es) | 2013-07-01 | 2016-03-21 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (dio). |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
-
2014
- 2014-07-01 MX MX2015017486A patent/MX2015017486A/es unknown
- 2014-07-01 BR BR112015032595A patent/BR112015032595A8/pt not_active Application Discontinuation
- 2014-07-01 CA CA2916615A patent/CA2916615A1/en not_active Abandoned
- 2014-07-01 JP JP2016524305A patent/JP2016528197A/ja not_active Ceased
- 2014-07-01 CN CN201480047995.5A patent/CN105473550B/zh not_active Expired - Fee Related
- 2014-07-01 ES ES14745007T patent/ES2719327T3/es active Active
- 2014-07-01 EP EP14745007.6A patent/EP3016932B1/en not_active Not-in-force
- 2014-07-01 US US14/897,668 patent/US9765018B2/en active Active
- 2014-07-01 WO PCT/US2014/044992 patent/WO2015002918A1/en not_active Ceased
- 2014-07-01 EA EA201690027A patent/EA029126B1/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528197A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2016519653A5 (enExample) | ||
| US11401259B2 (en) | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | |
| JP2016518324A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2018519245A5 (enExample) | ||
| JP2019529484A5 (enExample) | ||
| JP6644792B2 (ja) | ベンザゼピンスルホンアミド化合物 | |
| US9815813B2 (en) | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 | |
| JP2019517487A5 (enExample) | ||
| JP2015514056A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2014518544A5 (enExample) | ||
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| US20220054489A1 (en) | Aurora kinase inhibitors | |
| JP2014513731A5 (enExample) | ||
| CA2993809A1 (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| JP2013127001A (ja) | ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ剤 | |
| JP2013035853A (ja) | 増殖性疾患の処置または予防のためのピリミジルアミノベンズアミド化合物とイマチニブの組み合わせ | |
| JP2012526793A5 (enExample) | ||
| WO2015014283A1 (zh) | 蛋白酪氨酸激酶抑制剂及其应用 | |
| WO2024209717A1 (ja) | 腫瘍治療用医薬組成物 |